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Lessons from our e)(periences
Clearly the Department has been on Cl steep learning curve
in its desire to fulfil its mission and it has made mistakes.
Equally clearly, significant strides have also been made in
increasing access to health care. The commitment of the
Department to its mission cannot be questioned. A young
Department can but learn from its mistakes, and this
Department is as committed to this as it is to its mission.
The Department looks forward, with optimism, to the
challenges of the next 1 000 days and is committed to do
whatever it can to improve the health status of all South
Africans.
Accepted 21 JUly 1997.
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Background. A low-cost, 'flash' heat-inactivated hepatitis
B vaccine with enhanced immunogenicity allowing for a
relatively low dose (Hepaccine B; Cheil Foods and
Chemicals, Korea) was introduced into the South African
Expanded Programme on Immunisation during 1995 to
immunise infants against hepatitis B. To detennnine the
seroresponse of this vaccine in South Africa, a country
with a high hepatitis B virus (HBV) prevalence, a field trial
was conducted in a rural health clinic.
Methods. The immunogenicity of Hepaccine B,
containing 1.5IJg/O.5 ml, was studied in 186 black infants
attending the Soshanguve III clinic, north-west of Pretoria.
Infants receiving three consecutive doses in the
anterolateral thigh at 6,10 and 14 weeks were monitored.
The doses were administered concurrently with their
routine oral polio vaccine (OPV) and diphtheria, pertussis
and tetanus (DPT) immunisations. Vaccine side-effects
were recorded. Blood specimens were collected 3 months
after the final vaccination. Sera were tested for antibodies
to hepatitis B surface antigen (anti-HBs) by IMx AUSAB
(Abbott Laboratories, USA). Levels of anti-HBs were
determined by comparison with standard reference
preparations and expressed in mlUlml.
Results. Side-effects of the vaccine were minor, with
limited local reaction at the site of administration. The·
anti-HBs seroconversion rate was 93.0%, based on a titre
of ~ 10 mlUlml with a geometric mean titre of 257.58
mlUlml.
Conclusions. Administration of 1.5 I-Ig doses of
Hepaccine B at 6, 10 and 14 weeks is safe and highly
immunogenic in black South African infants, and this
vaccine is suitable for use in countries with high HBV
prevalences such as in Africa. The use of an economical
hepatitis B vaccine would greatly facilitate the prevention
of hepatitis B in these countries.
S Atr Med J 1998; 88: 36-39.
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Hepatitis B virus (HBV) infection is a serious public health
problem for many countries in the world. There are currently
at least 300 million HBV carriers globally, with an estimated
2 million residing in South Africa. Currently, effective and
immunogenic hepatitis B vaccines are available and have
brought hope for the prevention of hepatitis B. An effective
vaccination programme should take into account the unique
local epidemiological pattern, the health care delivery
system, and the social and resource implications. Although
genetically engineered hepatitis B vaccines are being
manufactured, the plasma-derived vaccines are still more
economical, especially if manufactured in a country with a
high prevalence of carriers. Hepaccine B, the vaccine used
in this study, is a multideterminant heat-inactivated hepatitis
B vaccine produced from human plasma by Cheil Foods and
Chemicals, Korea, based on technology licensed from the
New York Blood Center, USA.' Currently all plasma-derived
hepatitis B vaccines undergo inactivation procedures that
eliminate the risk of infection with blood-borne pathogens!
The controversy about plasma-derived vaccines arises from
the perception that blood-borne diseases such as AIDS
could be transmitted through plasma-derived vaccine.
Exhaustive tests have shown that this is not possible3 and
respected organisations such as the World Health
Organisation have fully endorsed the use of both types of
vaccine.' The South African Department of Health decided
to use a plasma-derived vaccine for two reasons: it was
shown to be as safe and effective as the recombinant
vaccine, and it was more affordable. Doses of 1.5 IJg
Hepaccine B in a 0-, 1- and 2-month schedule have been
approved for infants. The efficacy of this particular vaccine
is not an issue as it has been assessed previously and found
acceptable in principle for purchase by United Nations
agencies for infant immunisation programmes in developing
countries. Recently several reports pointed out the need to
evaluate the effectiveness of hepatitis B vaccination
regimens used in endemic countries since it cannot be
assumed that the manufacturer's recommendations apply to
a particular population.H We report on the adverse event
profile associated with administration of 1.5 IJg doses of
Hepaccine B hepatitis B vaccine at 6,10 and 14 weeks in
black South African babies as well as the good
seroresponse to the vaccine 3 months after the last
inoculation.
Participants and methods
Study population and immunisation
protocol
Approval for the study with a clearance certificate was
obtained from the Ethics Committee of the Faculty of
Medicine at the Medical University of Southern Africa, as
well as from the nursing manager of the Soshanguve clinics.
Three hundred and eleven babies attending the Soshanguve
III clinic, north-west of Pretoria, were enrolled in the study
and 0.5 ml (1.5 IJg) injections of Hepaccine B were
administered intramuscularly in the right anterolateral thigh
at 6, 10 and 14 weeks. No blood was collected from the
sUbjects prior to immunisation. The infants eligible for
Participation in the study were those who were to receive
oral polio virus (OPV) and diphtheria, pertussis and tetanus
(OPT) immunisations at 6 weeks. The doses were
administered concurrently with their routine OPV and OPT
immunisations. The vaccines were administered by the clinic
sisters, using 1 ml syringes and 1.5 E-1 needles.
Parental information and consent
The nursing sisters ensured that parents/guardians
understood the protocol by explaining in their own language
what vaccination is all about, the importance of taking the
full course of vaccination and the necessity of post-
vaccination blood sampling. Informed consent was
explained to parents or guardians of the infants as they were
recruited. Those who agreed were requested to sign a
consent form prior to the first dose.
Documentation and immunisation
monitoring
Each respondent was monitored in respect of name, age,
sex, address, birth weight, contact person, dates of
vaccination, post-vaccination follow-up and vaccine side-
effects. Pink calenders were attached to respondents' Road-
to-Health cards on which the date of the next clinic visit was
highlighted.
Methods for evaluation of vaccine
immunogenicity
Blood samples for post-vaccination testing. Blood was
collected from all infants who had received three doses of
vaccine, 3 months after the final dose, to test for
seroconversion and quantification of antibody levels. Three
millilitres of blood were taken from the jugular vein of the
respondents by qualified paediatricians at the clinic. Blood
samples were kept in a coldbox with ice-packs and
transported to the virology laboratory at MEDUNSA, where
samples were immediately centrifuged. The serum fractions
were stored at -20°C until tested.
Laboratory methods. Quantitated levels of antibodies to
hepatitis B surface antigen (anti-HBs) were determined in
the stored serum fractions using a microparticle enzyme
immunoassay (IMx AUSAB, Abbott Laboratories, USA). The
IMx System was calibrated using IMx AUSAB Calibrators
(Abbott Laboratories, USA) for each AUSAB reagent pack
that was used. The IMx AUSAB Calibrators have the
following concentrations of anti-HBs: 0, 10,50,100,500,1
000 mlU/ml. A positive control, a negative control and a
calibrator were run with each set of tests. Levels of anti-HBs
were determined by the IMx system in relation to the
calibration curve and expressed in mlU/ml. An antibody titre
(anti-HBs) of 10 mlUlml is regarded as the minimum
protective concentration against HBV infection" and in this
study we defined a titre of ;;", 10 mlU/ml as seroprotective.
Computerisation and analysis of the
results
All data from infants and the quantitated anti-HBs results
were entered into a PC using an Excel database
spreadsheet. Analysis of results was undertaken with the
Excel programme and the use of standard statistical
methods.
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Results
Characteristics of children given
Hepaccine B and compliance rate
The sampling of the children eligible for this study was
restricted to consecutive cases arriving on the immunisation
clinic days during the time of the study. It was further
restricted by the health of the child - parent/guardian
consent was not an issue as it was obtained in all cases. No
blood was collected prior to vaccination. Out of 311 infants
who received the first dose, 254 (81 %) returned for their
second dose. A total of 229 (73.6%) infants received three
doses of Hepaccine B, and 186 returned 3 months later for
blood collection.
Serological assays
Table I indicates the immunogenicity of Hepaccine B 3
months after the last dose in 186 infants tested. Although 13
babies had anti-HBs values below 10 mlU/ml, 6 babies were
hyporesponders who tested positive by the IMx AUSAB
assay with anti-HBs values between 2 and 9.9 mlU/ml. The
anti-HBs seroprotective rate based on a titre of ;;. 10 mlU/ml
was 93.0% with the 95% confidence intervals being
between 89.3% and 96.7%. The geometric mean titre was
257.58 mlU/ml and the arithmetic mean titre was 580.6
mlU/ml. A slightly higher seroconversion rate was found in
girls (95.4%) than in boys (90.9%), but with no significant
difference.
Table I. Immunogenicity of Hepaccine B 3 months after last dose,
in 186 infants tested (seroprotection ;;. 10 mlUlml = 93.0%)
Anti-HBs titre No. of infants %
< 10 mlU/ml 13 7
10 - 99.9 mlUlml 38 20.4
100 - 999.9 mlUlml 108 58.1
;;. 1 000 mlU/ml 27 14.5
Geometric mean titre 257.6 mlUlml
Side-effects of vaccination
Side-effects of the vaccine were minor, with limited local
reaction at the site of administration (Table 11).
Table 11. Side-effects of Hepaccine B vaccination (% monitored)
At injection site
Mild redness Haemorr-
Vacci- and mild rhagic Systemic
nation swelling Abscess necrosis fever
First 18/253 (7.1 %) None None 3/253 (1.1 %)
Second 18/232 (7.7%) None None 1/232 (0.4%)
Third 2/186 (1.1 %) None None 1/186 (0.5%)
Discussion
The objective of undertaking the exercise detailed in this
paper was to ascertain the immunogenicity of Hepaccine B
hepatitis B vaccine 3 months after the last dose when given
at 6, 10 and 14 weeks to South African infants. Our results
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revealed that this vaccine is safe and immunogenic in black
South African infants with an overall anti-HBs seroprotective
rate of 93.0% based on a titre of ;;. 10 mlU/ml. During
manufacture of Hepaccine B, no denaturing agents are
used, pre-S 1 and pre-S 2 antigen components are thus
preserved and a heat treatment step increases the
immunogenicity of the vaccine and inactivates any residual
activity. Our study confirms the good immunogenic
properties of Hepaccine B at this relatively low dose (1.5 IJg)
which has been reported in several independent studies in
Indonesia, Korea and the Philippines.9-" The post-
vaccination blood samples in this study were taken 3
months after the last inoculation at 27 weeks. In the
absence of pre-immunisation blood levels in this study it is
unlikely that high levels of maternal antibody could be
skewing our results. A previous study conducted in 1989 by
Manyike and colleagues12 showed that the overall HBV
exposure rate for the Ga-Rankuwa population (situated
close to Soshanguve) was 28.9%. Although no data were
collected for the 0 - 4-year age group, only 6% of children
had evidence of total HBV exposure in the 5 - 9-year age
group, 9.9% in the 10 - 15-year age group and 28.6% in the
20 - 24-year age group. From the low level of HBV
seropositivity and the absence of anti-HBs carriers in young
children in this population, it is unlikely that the 93% of
protective antibodies present in the infants could have
represented a boosting effect in infants already exposed to
the virus. Furthermore we now have evidence from recent
work indicating a 96% seroprotective rate of Hepaccine B at
9 months after babies have received the 3 doses at 6, 10
and 14 weeks. The good immunogenic properties of
Hepaccine B in this study and in other studies elsewhere in
the world contrasts with the only report by Milne and
colleagues: who conducted field evaluations of newborns in
Vanuatu and the Solomon Islands, where high failure rates
were observed even when larger doses of this vaccine were
used. Race or genetic factors could have accounted for the
difference in the results obtained from the different studies.
However, the decrease in anti-HBs levels in the South
African infants will continue to be monitored, as will the
occurrence of breakthrough infections.
The schedule of Hepaccine B is short: 0, 1, and 2 months.
This schedule has great benefit in reducing drop-outs and,
most importantly, the infants get their full protection earlier.
Although this study only evaluated seroconversion and
geometric mean titres 3 months after the third inoculation
and not after doses 1 and 2, the field trial conducted in
Indonesia showed that 97.41 % of infants seroconverted
after the first inoculation, 98.03% after the second
inoculation and 99.09% 3 months after the third inoculation
with geometric mean titres being 75.86, 114.81 and 128.82
mlUlml, respectively! Currently the populations of many
developing countries with high rates of hepatitis B infection
do not benefrt from hepatitis B vaccination, because of
misperceptions that plasma-derived hepatitis B vaccine may
be infectious and also that donors are not able to finance
expensive recombinant vaccine. The use of an affordable
hepatitis B vaccine, such as has been implemented in the
South African Expanded Programme on Immunisation and
elsewhere, would greatly facilitate the prevention of hepatitis
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Objective. To identify by means of genetic analyses
individuals who are at risk of developing medullary thyroid
cancer that is a component of multiple endocrine
neoplasia.
Subjects. A three-generation kindred with clinically and
biochemically diagnosed medUllary thyroid cancer.
Method. Identification of a heterozygote mutation by
nucleic acid sequencing and restriction analyses.
Results. A heterozygote T -t C (Cys -t Arg) mutation at
codon 618 in exon 10 of the RET proto-oncogene was
identified in 4 family members who had previously been
diagnosed with medullary thyroid cancer. The same
mutation was also found in one of the proband's pre-
symptomatic children who subsequently underwent a pre-
emptive thyroidectomy. The genetic diagnosis was
confirmed by histology. No mutations were detected in any
other family members.
Conclusion. Identification of heterozygote germline
mutations in multiple endocrine neoplasia is direct, highly
accurate and cost-effective. This study demonstrates that,
appropriately used, molecular diagnosis can supersede
conventional biochemical methods in the management of
patients with inherited cancers.
S Atr Med J 1997; 87: 39-42.
Medullary thyroid cancer (MTC) accounts for about 10% of
all thyroid tumours. It occurs mainly as a sporadic disease
but at least 25% of cases appear to be familial. The familial
form of W.TC occasionally manifests in isolation but usually
occurs as a component of either multiple endocrine
neoplasia (MEN) type 2A, comprising MTC,
phaeochromocytoma and hyperparathyroidism, or the rarer
MEN type 28 characterised by MTC, phaeochromocytoma,
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